| Identification | Back Directory | [Name]
6,9,12,15,18,21-Hexaoxa-3-azadocosanoic acid, 22-[3-[[[3-[[(2E)-2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazinyl]carbonyl]-4,5,6,7-tetrahydro-6,6-dimethylbenzo[b]thien-2-yl]amino]carbonyl]phenyl]-3-(2-methoxyethyl)- | [CAS]
1453116-06-7 | [Synonyms]
6,9,12,15,18,21-Hexaoxa-3-azadocosanoic acid, 22-[3-[[[3-[[(2E)-2-[[4-chloro-3-(trifluoromethyl)phenyl]methylene]hydrazinyl]carbonyl]-4,5,6,7-tetrahydro-6,6-dimethylbenzo[b]thien-2-yl]amino]carbonyl]phenyl]-3-(2-methoxyethyl)- | [Molecular Formula]
C44H58ClF3N4O11S | [MOL File]
1453116-06-7.mol | [Molecular Weight]
943.46 |
| Hazard Information | Back Directory | [Description]
NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. The inhibition of NaPi2b, responsible for intestinal phosphate absorption, is considered to reduce serum phosphate levels, making it a promising therapeutic approach for hyperphosphatemia |
|
|